VERIFIEDET Finance·23 May 2026positive

Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal

AI Summary

·Sun Pharma expects high single-digit overall sales growth by FY2027.
·The company is progressing with the integration of the $11.75 billion Organon deal.
·Organon acquisition completion is targeted for the last quarter of FY2027.